Medicine Recommendations

Localised neuropathic pain (as per LSCMMG Guidelines)

Localised neuropathic pain (as per LSCMMG Guidelines) and Hand and Knee Osteoarthritis (as per LSCMMG Guidelines)

Rheumatoid arthritis (LSCMMG pathway)

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Non-radiographic axial spondyloarthritis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Certolizumab pegol for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)

NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Rheumatic diseases, dermatology and severe ulcerative colitis

Acute Gout (as per LSCMMG Guidelines)

MHRA Drug Safety Update - Colchicine: extremely toxic in overdose

Treating Dupuytren's contracture (NICE TA459)

NICE TA459 - Collagenase clostridium histolyticum for treating Dupuytren's contracture

Rheumatic disease

Dibotermin alfa is recommended in Lancashire and South Cumbria for the treatment of acute tibia grade IIIB fractures in adults (as assessed on the Gustilo-Anderson scale), as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation in hospital settings.

Dibotermin alfa is not recommended in Lancashire and South Cumbria for use outside of the licensed indication for the treatment of non-union long bone fractures

Juvenile Idiopathic Arthritis (JIA) in Adult Patients

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis NICE TA373

Second line in psoriatic arthritis (PsA) following discontinuation of first anti-TNF due to an adverse event or primary or secondary inefficacy

Psoriatic arthritis (NICE TA199)

Non-radiographic axial spondyloarthritis (NICE TA383)

Ankylosing spondylitis (NICE TA383)

Hyperuricaemia in people with gout (NICE TA164)

MHRA Drug Safety Update - Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity

NICE TA676 - for treating moderate to severe rheumatoid arthritis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update